Naegis is attending ARVO 2024   May 5th 9th  |  Seattle

Our Team

Naegis is led by a team of experienced drug discovery and development scientists supported by an exceptional Board of Directors and Advisors who together have multiple years leadership experience in major ophthalmic companies.

Board of Directors

Julian Gangolli

Chairman of the Board

Mr. Gangolli has a well-established track record in the ophthalmic industry having joined Allergan in 1998 as Senior Vice President US Eye Care.  He served as President of the North American Pharmaceutical division of Allergan, Inc. for 11 years where he was responsible for a 1,400-person commercial operation with sales exceeding $3.8 billion. As a member of the Allergan Executive Committee, he was part of the select team that executed the sale of Allergan to Actavis in 2015 for US$66 billion.

Ian McBeath

Chief Executive Officer

Mr. McBeath has more than 35 years’ experience in the biopharmaceutical industry. He was a senior executive with major pharmaceutical companies prior to the founding of 3 biotech companies, one of which was sold to Amgen for $1 billion. He has led companies involved in drug discovery, research & development and commercialization and raised significant levels of start-up and follow-on financing and taken one company to a public listing.

Dr. David Burgoyne


Dr. Burgoyne has more than 25 years’ experience in drug discovery and development.  He obtained his PhD in Chemistry from the University of British Columbia. His research directly led to an anti-inflammatory compound that became the founding technology for Inflazyme Pharmaceuticals, a Vancouver based company developing new asthma treatments.  With Inflazyme, Dr. Burgoyne worked as VP Research advancing multiple products and later VP Business Development using his expertise for licensing and mergers & acquisitions. He founded Naegis to expand research and identify novel molecules that target mechanisms resulting in first-in-class treatments for serious inflammatory diseases. These molecules are the basis for Naegis’ development of new treatments for serious ophthalmic diseases.

Dr. Philip Davies


Dr. Davies is an expert in inflammatory mechanisms and pharmacology.  He joined Merck Pharmaceuticals in 1975 to establish research on novel mechanism anti-inflammatory drugs.  He served for over 25 years including as Executive Director and Head of Immunology Research focused on immune and non-immune inflammatory diseases.  He received his PhD from the Welsh National School of Medicine and post-doctoral training at New York School of Medicine.

Cameron Groome


Mr. Groome has over 25 years of experience in the life sciences and finance industries.  He has worked as an Analyst, Investment Banker and Corporate Advisor and has helped enable the growth of many biopharmaceutical companies.  He currently is Chief Executive Officer of Microbix Biosystems Inc. a manufacturer of critical biological materials, such as antigens, for the global diagnostics industry.

Michael Liggett


Mr. Liggett has over 30 years’ experience in the health care and finance industries.  After 7 years working as a Hospital Pharmacist, Mr. Liggett trained and qualified as a Chartered Accountant with Price Waterhouse before joining Vancouver-based Inflazyme Pharmaceuticals as CFO. With Inflazyme he provided leadership through a number of financings and was part of the team that took the Company public on the Toronto Stock Exchange.

R&D Team

Dr. John Langlands

IND Development

Dr. John Langlands received his Doctorate in Respiratory Pharmacology from the University of Strathclyde in Glasgow. He held postdoctoral Fellowships from the BC & Yukon Heart Foundation and the Canadian and BC Lung Associations at the University of British Columbia, Vancouver. He has over 30 years of experience directed towards the development of new medicines and has been involved in preclinical and clinical translational medicine approaches to drug development, the integration of various aspects of the drug development life cycle, and early access programs (EAP) bringing therapies to patients with difficult-to- treat conditions and limited treatment options. Dr. Langlands has held senior management positions in preclinical and clinical research at Inflazyme Pharmaceuticals from 1994 to 2007 and senior lecturer and program director for pharmaceutical medicine & drug development at UNSW in Sydney (AU) from 2009 to 2012. He has been owner and principal of Langlands & Associates Consulting Inc since 2008, acting as an independent consultant to several biopharmaceutical companies. He has also been serving as head of clinical operations at DelMar Pharmaceuticals/Kintara Therapeutics, chief operating officer at Rakovina Therapeutics, and is co-founder and advisor to MedaSystems. At Naegis Dr Langlands is responsible for oversight of IND- enabling studies and is a key member of the clinical development strategy team. He is a member of SNO and was a founding and past Chair of Vancouver Pharmaceutical and BioScience Society (PBSS).

Dr. Peter Hnik

Clinical Ophthalmology

Dr. Hnik received his medical degree from the Medical Faculty of Charles University of Prague in 1981. After practicing at the Eye Clinic of the Charles University Hospital where he was involved in treatment of glaucoma, ocular inflammation, diseases of retina and neuro-ophthalmology, he later joined the Eye Clinic of the University of British Columbia as part of the glaucoma research group. He received his Master of Health Sciences degree from the University of British Columbia in 1999. Between 1999 and 2006, Dr. Hnik served as Associate Director of Clinical Research with QLT Inc., designing and directing clinical trials in AMD and diabetic retinopathy. Since 2006, he has been active as a president and owner of Clinscape Consulting Inc. providing clinical guidance to multiple biotech and pharma companies & financial institutions. Dr. Hnik has also been serving as Chief Medical Officer with iCo Therapeutics Inc. leading all clinical programs, participating in meetings with financial institutions/investors and assessing new in-licensing opportunities. He has authored numerous ocular publications and presentations at international forums. Dr. Hnik has been a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), the Drug Information Association (DIA), and the New York Academy of Sciences (NYAS).

Dr. James Yee


Dr. Yee completed his doctoral studies in synthetic organic chemistry at the University of British Columbia with Edward Piers. He completed postdoctoral training at the University of Nottingham with Professor Gerald Pattenden and contributed to the total synthesis of Ulapualide A. With over twenty years of industrial experience, he has expertise in the advancement of small molecule preclinical candidates and Chemistry Manufacturing and Controls management. James has been a key contributor to Naegis Pharmaceuticals’ technology development since inception and is currently the Director of Chemistry.

Scientific Advisory Board

Dr. Julia Levy

Advisory Board

Co-founder and CEO of QLT, the company thought brought one of the first
products to market for age-related macular degeneration.

Dr. Philip Rosenfeld

Advisory Board

Dr. Rosenfeld is currently Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Health System.  He is a world-renowned expert on age-related macular degeneration (AMD) and optical coherence tomography (OCT) and a pioneer of anti-VEGF treatments.

Dr. Virginia Calder

Advisory Board

Dr. Calder is Professor of Ocular Immunology, University College London, Institute of Ophthalmology.  She is an expert in immune mechanisms in chronic inflammatory eye diseases and her work has significantly advanced the understanding of the role of leukotrienes in inflammatory eye disease.

Dr. David Saperstein

Advisory Board

Dr. Saperstein is a Retinal Surgeon with Pacific Retina in Seattle Washington. He completed his Fellowship at Emory University in Atlanta and served as Chief Retinal Surgeon at Grady Hospital in Atlanta and later at Harbourside Hospital in Seattle. Dr. Saperstein has been Primary Investigator or on the Steering Committee for many of the clinical trials into treatments for retinal diseases.  He has been involved in the discovery of a number of new drugs for retinal disease and surgical and low vision devices for which he holds a number of patents.

Dr. Alan Weiner

Pharmaceutical Consultant

Dr. Weiner is an expert in development of drug delivery and formulation development having been Senior Director at Alcon Research Ltd. where he directed the formulation development of over 30 ophthalmic products. Prior to joining Alcon, Dr. Weiner was the founding scientist of two drug delivery companies.

Partnering: The Opportunities Beyond Eye Disease

Leukotrienes are known to have a role in many other inflammatory disease such as serious lung disease, cardiovascular disease and cancer, among others. Our core focus at this time is on ophthalmology. To access the broader opportunities for our proprietary compound library and multiple potential lead candidates, we are open to talking with companies who are interested in working with us to accelerate programs towards new treatments for other inflammatory diseases.